BioCopy's CEO Matthias Wiedenfels among Germany's biotech pioneers of the coming decade

Tuesday, December 17, 2024 @ 12:00 am

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.

BioCopy AG is proud to announce that the renowned WirtschaftsWoche, a medium of the Handelsblatt Media Group, has selected Matthias Wiedenfels as the winner of "Germany's 30 by 2030". With this award, the editorial team honors 30 outstanding personalities who have made a significant contribution to shaping Germany's future by 2030 with their innovative strength and commitment.

A stage for courage and innovative spirit
In its initiative, WirtschaftsWoche highlights thought leaders and pioneers from business, science and society who stand for courage, unconventional approaches and breakthroughs, thereby strengthening and advancing Germany economically. For BioCopy, honoring Mr. Wiedenfels is a special recognition of his special commitment to developing novel therapeutics tocure cancer with disruptive approaches and proprietary technologies.

"Our goal is to develop effective and safe drugs for cancer treatment through a unique combination of artificial intelligence and experimental laboratory data and to establish Germany as a leader in this field," says Matthias Wiedenfels. "This award goes to the entire BioCopy team, without whom we would not be able to achieve our quantum leap in cancer therapy," emphasizes Wiedenfels.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

The co-founders of AlphaMol are ranked as the "top 2% scientists" in the world

December 16, 2024

Porton Pharma Solutions: Collaboration with Aojin Life Sciences in China and USA

December 13, 2024

MedScienceSwiss: Combatting antibiotic-resistant bacteria with “Plan B”

MedScienceSwiss is developing a non-pharmaceutical therapy for the treatment of antibiotic-resistant bacteria. The goal: to significantly reduce the number of deaths in hospitals due to nosocomial (difficult-to-treat) infections. The technology is not only intended to serve as an alternative to the current plan A (antibiotics), but also to function as a general approach to the treatment of resista
December 3, 2024

Leman Biotech: New indication for CAR-T therapy for non-Hodgkin lymphoma patients

The First Affiliated Hospital of Zhejiang University School of Medicine recently held the clinical launch meeting for an expansion of the investigator-initiated clinical trial (IIT) to include relapsed or refractory indolent B-cell non-Hodgkin lymphoma (r/r B-iNHL) as a new indication for Leman Biotech's metabolically armed CD19 CAR-T therapy, Meta10-19 therapy. The clinical protocol focuses on pr
November 29, 2024